The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories's revenues will grow 0.9% and EPS will grow 8.5%.
The average estimate for revenue is $9.91 billion. On the bottom line, the average EPS estimate is $1.28.
Last quarter, Abbott Laboratories tallied revenue of $9.81 billion. GAAP reported sales were 2.0% higher than the prior-year quarter's $9.62 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.23. GAAP EPS of $1.08 for Q2 were 12% lower than the prior-year quarter's $1.23 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 62.9%, 310 basis points better than the prior-year quarter. Operating margin was 22.6%, 240 basis points better than the prior-year quarter. Net margin was 17.6%, 260 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $39.76 billion. The average EPS estimate is $5.06.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,551 members out of 2,643 rating the stock outperform, and 92 members rating it underperform. Among 665 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 648 give Abbott Laboratories a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is hold, with an average price target of $64.33.
Can your retirement portfolio provide you with enough income to last? You'll need more than Abbott Laboratories. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Abbott Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
ABT earnings call for the period ending September 30, 2017